1887

Abstract

is a common cause of meningoencephalitis among AIDS patients. Several virulence factors have been identified, but the relative importance of particular factors is unknown. This study examined the corrrelation of the virulence of 18 var. isolates from AIDS patients with the expression of several well-described virulence factors. The LD at 15 days after intracranial inoculation of ICR mice was <100 c.f.u. for 22 % of isolates, 100–1000 for 28 %, 1000–10 000 for 11 % and >20 000 for 39 %. Higher cryptococcal concentrations in brains were noted for isolates with lower LD (=0.002). In survival studies, no immunocompetent BALB/c mice (/−) infected with 3×LD of three virulent isolates (LD=62, 99, 1280) survived beyond 23 days, whereas 100 %, 90 % and 90 % of mice infected with 20 000 c.f.u. of three hypovirulent isolates (LD>20 000) survived for 60 days (<0.0001). Even among BALB/c nude (/) mice, survival rates over 60 days were 100 %, 70 % and 50 %, respectively, for the hypovirulent isolates. Growth rate at 37 °C and capsule size within brains correlated with LD by univariate (=0.0001 and 0.028, respectively) and multivariate (=0.017 and 0.016, respectively) analyses. There was no correlation between LD and capsule size , phospholipase activity, melanin formation, proteinase activity and fluconazole MIC. In conclusion, AIDS patients are susceptible to infection by isolates of wide-ranging virulence, including isolates that are markedly hypovirulent. The virulence of a given isolate reflects a composite of factors rather than the contribution of a dominant factor. Growth at 37 °C and capsule size make particularly important contributions.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.28798-0
2006-08-01
2020-08-15
Loading full text...

Full text loading...

/deliver/fulltext/micro/152/8/2247.html?itemId=/content/journal/micro/10.1099/mic.0.28798-0&mimeType=html&fmt=ahah

References

  1. Andrade V. S, Sarubbo L. A, Fukushima K, Miyaji M, Nishimura K, de Campos-Takaki G. M. 2002; Production of extracellular proteases by Mucor circinelloides using d-glucose as carbon source/substrate. Braz J Microbiol33:106–110
    [Google Scholar]
  2. Barchiesi F, Cogliati M, Esposto M. C, Spreghini E, Schimizzi A. M, Wickes B. L, Scalise G, Viviani M. A. 2005; Comparative analysis of pathogenicity of Cryptococcus neoformans serotypes A, D and AD in murine cryptococcosis. J Infect51:10–16[CrossRef]
    [Google Scholar]
  3. Blackstock R, Murphy J. W. 1997; Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans . Infect Immun65:4114–4121
    [Google Scholar]
  4. Blackstock R, Buchanan K. L, Cherniak R, Mitchell T. G, Wong B, Bartiss A, Jackson L, Murphy J. W. 1999; Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors. Mycopathologia147:1–11[CrossRef]
    [Google Scholar]
  5. Blasi E, Barluzzi R, Mazzolla R, Mosci P, Bistoni F. 1992; Experimental model of intracerebral infection with Cryptococcus neoformans : roles of phagocytes and opsonization. Infect Immun60:3682–3688
    [Google Scholar]
  6. Blasi E, Barluzzi R, Mazzolla R, Tancini B, Saleppico S, Puliti L, Pitzurra M, Bistoni F. 1995; Role of nitric oxide and melanogenesis in the accomplishment of anticryptococcal activity by the BV-2 microglial cell line. J Neuroimmunol58:111–116[CrossRef]
    [Google Scholar]
  7. Casadevall A, Perfect J. R. 1998; Cryptococcus neoformans Washington, DC: American Society for Microbiology;
    [Google Scholar]
  8. Casadevall A, Rosas A. L, Nosanchuk J. D. 2000; Melanin and virulence in Cryptococcus neoformans . Curr Opin Microbiol3:354–358[CrossRef]
    [Google Scholar]
  9. Chang Y. C, Kwon-Chung J. K. 1994; Complementation of a capsule-deficiency mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol14:4912–4919
    [Google Scholar]
  10. Chang Y. C, Kwon-Chung J. K. 1998; Isolation of the third capsule-associated gene, CAP60 , required for virulence in Cryptococcus neoformans . Infect Immun66:2230–2236
    [Google Scholar]
  11. Chang Y. C, Kwon-Chung J. K. 1999; Isolation, characterization, and localization of a capsule-associated gene, CAP10 , of Cryptococcus neoformans . J Bacteriol181:5636–43
    [Google Scholar]
  12. Chang Y. C, Penoyer L. A, Kwon-Chung K. J. 1996; The second capsule gene of Cryptococcus neoformans, Cap64 , is essential for virulence. Infect Immun64:1977–1983
    [Google Scholar]
  13. Chen L. C, Blank E. S, Casadevall A. 1996; Extracellular proteinase activity of Cryptococcus neoformans . Clin Diagn Lab Immunol3:570–574
    [Google Scholar]
  14. Chen S. C. A, Muller M, Zhou J. Z, Wright L. C, Sorrell T. C. 1997; Phospholipase activity in Cryptococcus neoformans : a new virulence factor?. J Infect Dis175:414–420[CrossRef]
    [Google Scholar]
  15. Collins H. L, Bancroft G. J. 1991; Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect Immun59:3883–3888
    [Google Scholar]
  16. Cox G. M, McDade H. C, Chen S. C. A.8 other authors 2001; Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans . Mol Microbiol39:166–175[CrossRef]
    [Google Scholar]
  17. Curtis J. L, Huffnagle G. B, Chen G. H, Warnock M. L, Gyetko M. R, McDonald R. A, Scott P. J, Toews G. B. 1994; Experimental murine pulmonary cryptococcosis: differences in pulmonary inflammation and lymphocyte recruitment induced by two encapsulated strains of Cryptococcus neoformans . Lab Invest71:113–126
    [Google Scholar]
  18. Cutler J. E. 1991; Putative virulence factors of Candida albicans . Annu Rev Microbiol45:187–218[CrossRef]
    [Google Scholar]
  19. Dixon D. M, Polak A. 1986; In vivo and in vitro studies with an atypical, rhinotrophic isolate of Cryptococcus neoformans . Mycopathologia96:33–96 40[CrossRef]
    [Google Scholar]
  20. Dong Z. M, Murphy J. W. 1995; Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect Immun63:2632–2644
    [Google Scholar]
  21. Dykstra M. A, Friedman L, Seed B. 1977; Capsule size of Cryptococcus neoformans : control and relationship to virulence. Infect Immun16:129–135
    [Google Scholar]
  22. Feldmesser M, Kress Y, Casadevall A. 2001; Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology147:2355–65
    [Google Scholar]
  23. Franzot S. P, Mukherjee J, Cherniak R, Chen L, Hamdan J. S, Casadevall A. 1998; Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun66:89–97
    [Google Scholar]
  24. Fries B. C, Casadevall A. 1998; Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J Infect Dis178:1761–1766[CrossRef]
    [Google Scholar]
  25. Fromtling R. A, Abruzzo G. K, Ruiz A. 1988; Cryptococcus neoformans : a central nervous system isolate from an AIDS patient that is rhinotropic in a normal mouse model. Mycopathologia102:72–86
    [Google Scholar]
  26. Garcia-Hermoso D, Dromer F, Janbon G. 2004; Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun72:3359–3365[CrossRef]
    [Google Scholar]
  27. Grosse G, Mishra S. K, Staib F. 1975; Selective involvement of the brain in experimental murine cryptococcosis. II. Histopathological observations. Zentralbl Bakteriol230:518–533
    [Google Scholar]
  28. Hasenclever H. F, Mitchell W. O. 1960; Virulence and growth rates of Cryptococcus neoformans in mice. Ann N Y Acad Sci89:156–62
    [Google Scholar]
  29. Iwata K, Yamashita T, Ohsumi M, Baba M, Naito N, Taki A, Yamada N. 1990; Comparative morphological and biological studies on the itraconazole- and ketoconazole-resistant mutants of Cryptococcus neoformans . J Med Vet Mycol28:77–90[CrossRef]
    [Google Scholar]
  30. Jacobson E. S, Emery H. S. 1991; Catecholamine uptake, melanization, and oxygen toxicity in Cryptococcus neoformans . J Bacteriol173:401–403
    [Google Scholar]
  31. Janbon G. 2004; Cryptococcus neoformans capsule biosynthesis and regulation. FEMS Yeast Res4:765–771[CrossRef]
    [Google Scholar]
  32. Kagaya K, Yamada T, Miyakawa Y, Fukazawa Y, Saito S. 1985; Characterization of pathogenic constituents of Cryptococcus neoformans strains. Microbiol Immunol29:517–532[CrossRef]
    [Google Scholar]
  33. Kozel T. R. 1995; Virulence factors of Cryptococcus neoformans . Trends Microbiol3:295–299[CrossRef]
    [Google Scholar]
  34. Kwon-Chung K. J, Rhodes J. C. 1986; Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans . Infect Immun51:218–223
    [Google Scholar]
  35. Kwon-Chung K. J, Polacheck I, Popkin T. J. 1982; Melanin-lacking mutants of Cryptococcus neoformans and their virulence for mice. J Bacteriol150:1414–1421
    [Google Scholar]
  36. Kwon-Chung K. J, Wickes B. L, Stockman L, Roberts G. D, Ellis D, Howard D. H. 1992; Virulence, serotype, and molecular characteristics of environmental strains of Cryptococcus neoformans var. gattii . Infect Immun60:1869–1874
    [Google Scholar]
  37. Leighton T. J, Doi R. H, Warren R. A. J, Kelln R. A. 1973; The relationship of serine protease activity to RNA polymerase modification and sporulation in Bacillus subtilis . J Mol Biol76:103–122[CrossRef]
    [Google Scholar]
  38. Littman M. L, Tsubura E. 1959; Effect of degree of encapsulation upon virulence of Cryptococcus neoformans . Proc Soc Exp Biol Med101:773–776[CrossRef]
    [Google Scholar]
  39. Macher A. M, Bennett E, Gadek J. E, Frank M. M. 1978; Complement depletion in cryptococcal sepsis. J Immunol120:1686–1690
    [Google Scholar]
  40. Mitchell T. G, Perfect J. R. 1995; Cryptococcosis in the era of AIDS – 100 years after the discovery of Cryptococcus neoformans . Clin Microbiol Rev8:515–548
    [Google Scholar]
  41. National Committee for Clinical Laboratory Standards 1997; Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts . Approved standard. Document M-27A Wayne, PA: National Committee for Clinical Laboratory Standards;
    [Google Scholar]
  42. Nielsen K, Cox G, Wang P, Toffaletti D, Perfect J. R, Heitman J. 2003; Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and α isolates. Infect Immun71:4831–4841[CrossRef]
    [Google Scholar]
  43. Nosanchuk J. D, Casadevall A. 2003; Budding of melanized Cryptococcus neoformans in the presence or absence of l-dopa. Microbiology149:1945–1951[CrossRef]
    [Google Scholar]
  44. Noverr M. C, Williamson P. R, Fajardo R. S, Huffnagle G. B. 2004; CNLAC1 is required for extrapulmonary dissemination of Cryptococcus neoformans but not pulmonary persistence. Infect Immun72:1693–1699[CrossRef]
    [Google Scholar]
  45. Polacheck I, Hearing V. J, Kwon-Chung K. J. 1982; Biochemical studies of phenoloxidase and utilization of catechalamines in Cryptococcus neoformans . J Bacteriol150:1212–1220
    [Google Scholar]
  46. Polak-Wyss A. 1991; Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses34:205–215
    [Google Scholar]
  47. Retini C, Vecchiatelli A, Monari C, Tascini C, Bistoni F, Kozel T. R. 1996; Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun64:2897–2903
    [Google Scholar]
  48. Rhodes J. C, Polacheck I, Kwon-Chung K. J. 1982; Phenoloxidase activity and virulence in isogenic strains of Cryptococcus neoformans . Infect Immun36:1175–1184
    [Google Scholar]
  49. Rivera J, Feldmesser M, Cammer M, Casadevall A. 1998; Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun66:5027–5030
    [Google Scholar]
  50. Salas S. D, Bennett J. E, Kwon-Chung K. L, Perfect J. R, Williamson P. R. 1996; Effect of the laccase gene CNLAC1 , on virulence of Cryptococcus neoformans . J Exp Med184:377–86[CrossRef]
    [Google Scholar]
  51. Vanbreuseghem R. 1967; White mice sensitivity to Cryptococcus neoformans . Production of resistance against a cerebral inoculation. Ann Soc Belg Med Trop47:281–294
    [Google Scholar]
  52. Van Cutsem J, Fransen J, Van Gerven F, Janssen P. A. J. 1986; Experimental cryptococcosis: dissemination of Cryptococcus neoformans and dermatropism in guinea pigs. Mykosen29:561–575
    [Google Scholar]
  53. Vecchiarelli A, Retini C, Pietrella D, Monari C, Tascini C, Beccari T, Kozel T. T. 1995; Down-regulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect Immun63:2919–2923
    [Google Scholar]
  54. Vecchiarelli A, Retini C, Monari C, Tascini C, Bistoni F, Kozel T. R. 1996; Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun64:2846–2849
    [Google Scholar]
  55. Velez J. D, Allendoerfer R. R, Luther M, Rinaldi M. G, Graybill J. R. 1993; Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis168:508–510[CrossRef]
    [Google Scholar]
  56. Williamson P. R. 1997; Laccase and melanin in the pathogenesis of Cryptococcus neoformans . Front Biosci2:e99–e107
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.28798-0
Loading
/content/journal/micro/10.1099/mic.0.28798-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error